{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:19:25Z","timestamp":1788470365170,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urolonc.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:26:29Z","timestamp":1787862389000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic landscape of upper tract urothelial carcinoma: Intraluminal agents, perioperative chemotherapy, and immunotherapy"],"prefix":"10.1016","author":[{"given":"Sri Saran","family":"Manivasagam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupret","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines(R) insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0004","article-title":"Genotype-phenotype characterization of Lynch Syndrome-associated upper tract urothelial carcinoma","author":"Labbate","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040664","article-title":"Risk factors predictive of contralateral recurrence of upper tract urothelial carcinoma include chronic kidney diseases and postoperative initiation of dialysis","volume":"17","author":"Wu","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euros.2023.01.004","article-title":"Bladder recurrence following upper tract surgery for urothelial carcinoma: a contemporary review of risk factors and management strategies","volume":"49","author":"Mertens","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0007","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bju.15925","article-title":"Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study","volume":"131","author":"Rose","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0008","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.euf.2023.05.012","article-title":"Route of administration for UGN-101 and impact on oncological and safety outcomes","volume":"9","author":"Linehan","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0009","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.21037\/tau-23-69","article-title":"Advances in chemoablation in upper tract urothelial carcinoma: overview of indications and treatment patterns","volume":"12","author":"Gottlieb","year":"2023","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1089\/end.2012.0211","article-title":"Increasing dwell time of mitomycin C in the upper tract with a reverse thermosensitive polymer","volume":"27","author":"Wang","year":"2013","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2013.08.048","article-title":"Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model","volume":"82","author":"Pollard","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0012","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1590\/s1677-5538.ibju.2016.0258","article-title":"Which is best method for instillation of topical therapy to the upper urinary tract? An in vivo porcine study to evaluate three delivery methods","volume":"43","author":"Liu","year":"2017","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0013","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/end.2016.0871","article-title":"Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: tolerability and intermediate term outcomes","volume":"31","author":"Metcalfe","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/end.2019.0750","article-title":"Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre prospective non-randomized trial","volume":"34","author":"Gallioli","year":"2020","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/0974-7796.115746","article-title":"Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma","volume":"5","author":"Aboumarzouk","year":"2013","journal-title":"Urol Ann"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937950","article-title":"UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma","volume":"12","author":"Kokorovic","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0017","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0018","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.euf.2023.03.016","article-title":"Mitomycin gel (UGN-101) as a kidney-sparing treatment for upper tract urothelial carcinoma in patients with imperative indications and high-grade disease","volume":"9","author":"Rose","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0019","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00280-021-04246-w","article-title":"Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma","volume":"87","author":"Shabsigh","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0021","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/JU.0000000000004331","article-title":"Long-term outcomes of primary chemoablation of low-grade upper tract urothelial carcinoma with UGN-101, a mitomycin reverse thermal gel","volume":"213","author":"Pierorazio","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0022","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.21037\/tau-23-35","article-title":"Adjuvant intraluminal therapies for upper tract urothelial carcinoma","volume":"12","author":"Khargi","year":"2023","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0023","article-title":"A systematic review of intracavitary therapies for upper tract urothelial carcinoma","author":"Wong","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0024","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0022-5347(05)64454-0","article-title":"Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery","volume":"168","author":"Thalmann","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0025","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.urology.2004.01.046","article-title":"Long-term effects of bacille Calmette-Guerin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract","volume":"63","author":"Hayashida","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0026","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","article-title":"Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?","volume":"60","author":"Giannarini","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","article-title":"A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy?","volume":"73","author":"Rastinehad","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0028","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1089\/end.2012.0229","article-title":"Outcomes of intrarenal Bacillus Calmette-Guerin\/interferon-alpha2B for biopsy-proven upper-tract carcinoma in situ","volume":"26","author":"Shapiro","year":"2012","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0029","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/end.2007.9969","article-title":"Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B","volume":"21","author":"Katz","year":"2007","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0030","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.urolonc.2022.11.001","article-title":"Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary tract carcinoma in situ: a single institution series and systematic review","volume":"41","author":"Fontanet","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0031","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00345-018-2349-9","article-title":"Salvage topical therapy for upper tract urothelial carcinoma","volume":"36","author":"Balasubramanian","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0032","doi-asserted-by":"crossref","first-page":"20.e9","DOI":"10.1016\/j.urolonc.2023.08.013","article-title":"Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma","volume":"42","author":"McElree","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.08.002","article-title":"Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients","volume":"39","author":"Katims","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0034","article-title":"A phase 2\/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma","volume":"43","author":"Marie-Pier St-Laurent","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0035","doi-asserted-by":"crossref","first-page":"194.e191","DOI":"10.1016\/j.urolonc.2020.07.028","article-title":"A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma","volume":"39","author":"Kesch","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.09.015","article-title":"Endoscopic thulium laser ablation with Disitamab Vedotin and immunotherapy in high-risk upper tract urothelial carcinoma: a prospective pilot study of a novel kidney-sparing strategy","author":"Ye","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0037","unstructured":"SeqUential GeMcitabine and MITomycin treatment for favorable high-risk upper urinary tract urothelial carcinoma; 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06822010"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijpharm.2016.08.061","article-title":"Drug-eluting biodegradable ureteral stent: new approach for urothelial tumors of upper urinary tract cancer","volume":"513","author":"Barros","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0039","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.xphs.2017.02.023","article-title":"In Vitro and ex vivo permeability studies of Paclitaxel and Doxorubicin from drug-eluting biodegradable ureteral stents","volume":"106","author":"Barros","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0040","article-title":"Assessment of a coated mitomycin-releasing biodegradable ureteral stent as an adjuvant therapy in upper urothelial carcinoma: a comparative In vitro study","volume":"14","author":"Soria","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0041","doi-asserted-by":"crossref","first-page":"194","DOI":"10.23736\/S2724-6051.23.05152-2","article-title":"Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma","volume":"75","author":"Soria","year":"2023","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/polym14194081","article-title":"Cytotoxicity assessment of a new design for a biodegradable ureteral mitomycin drug-eluting stent in urothelial carcinoma cell culture","volume":"14","author":"Soria","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0043","article-title":"ENLIGHTED phase 3 study: interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC)","volume":"43","author":"Vitaly","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0044","unstructured":"Phase 2A\/B efficacy and safety of Dabogratinib in participants with low grade upper tract urothelial carcinoma (SURF303); 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07265947"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS906","article-title":"LUNAR: safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma\u2014a single-arm, open-label phase 1\/2 trial","volume":"44","author":"Lerner","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0046","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/bju.16655","article-title":"Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma","volume":"135","author":"Yu","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0047","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0048","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.eururo.2025.08.012","article-title":"Neoadjuvant chemotherapy for high-risk localized upper tract urothelial carcinoma: final long-term outcomes from a phase 2 clinical trial and an expanded cohort","volume":"89","author":"Jayalath","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0049","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.urolonc.2024.11.025","article-title":"The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: results from the upper tract collaborative network (UCAN)","volume":"43","author":"Carpinito","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0050","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.euf.2017.03.013","article-title":"Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma","volume":"4","author":"Hosogoe","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0051","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","article-title":"Multicenter phase II clinical trial of Gemcitabine and Cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma","volume":"41","author":"Coleman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0052","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0053","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JU.0000000000000737","article-title":"Efficacy of preoperative chemotherapy for high risk upper tract urothelial carcinoma","volume":"203","author":"Foerster","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0054","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and Adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-14966-4","article-title":"The efficacy of neoadjuvant therapy for upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"25","author":"Zhong","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0056","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/jjco\/hyad118","article-title":"Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study","volume":"53","author":"Takahashi","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-025-06061-x","article-title":"Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma in the setting of clinical node positive disease: analysis of the ROBUUST registry","volume":"44","author":"Meagher","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0058","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO-25-00179","article-title":"Safety and efficacy of Neoadjuvant Durvalumab plus gemcitabine\/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT-GETUG V08 trial","volume":"43","author":"Houede","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0059","article-title":"Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: preliminary results from a phase II study","volume":"43","author":"Xingang Bi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.345","article-title":"A phase II study of tislelizumab(T) as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC)","volume":"34","author":"Huang","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0061","unstructured":"Study of neoadjuvant enfortumab vedotin and pembrolizumab in Cisplatin-eligible upper tract urothelial cancer (NEPTUNE); 2025."},{"key":"10.1016\/j.urolonc.2026.08.002_bib0062","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0063","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0064","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0066","doi-asserted-by":"crossref","first-page":"697.e611","DOI":"10.1016\/j.urolonc.2025.07.014","article-title":"Efficacy of adjuvant nivolumab in patients with upper tract predominant urothelial carcinoma: a single-center real-world study","volume":"43","author":"Chen","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0067","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab Vedotin plus Toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0068","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/iju.70136","article-title":"Real-world outcomes of first-line systematic treatment in locally advanced or metastatic upper urinary tract urothelial carcinoma with renal impairment (YUSHIMA Study)","volume":"32","author":"Kimura","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0069","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0070","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102453","article-title":"Real-world outcomes of Enfortumab Vedotin and Pembrolizumab in advanced urothelial carcinoma: a multicenter retrospective analysis","volume":"23","author":"Jain","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0072","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00262-025-04154-5","article-title":"The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study","volume":"74","author":"Ng","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","article-title":"Clinical and genomic landscape of FGFR3 alterations across different stages of urothelial cancer","volume":"77","author":"Haas","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.08.002_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1151701","article-title":"Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis","volume":"13","author":"Rouvinov","year":"2023","journal-title":"Front Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:36:36Z","timestamp":1788467796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":74,"alternative-id":["S1078143926006964"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic landscape of upper tract urothelial carcinoma: Intraluminal agents, perioperative chemotherapy, and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}